Literature DB >> 11114562

Advancements in pharmacologic management of the overactive bladder.

R R Dmochowski1, R A Appell.   

Abstract

Continued developments in the understanding of lower urinary tract function have led to improvements in the pharmacologic manipulation of bladder dysfunction. Drug delivery changes have produced drugs that provide better efficacy and tolerability, thus improving patient compliance. Improvements in drug delivery systems have altered drug bioavailability and pharmacokinetics. Active current investigation in new agents and delivery systems for intravesical delivery has yielded intriguing early results that may substantially add to the armamentarium for the management of the overactive bladder (urgency, frequency, urge incontinence). New developments in the understanding of the neuropharmacology of the bladder, peripheral pelvic nerves, and sacral cord may provide agents with entirely new drug effects, either as primary agents or agents to be used in combination with currently available drugs. We herein review newer agents and drug delivery systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114562     DOI: 10.1016/s0090-4295(00)01020-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

Review 1.  Trospium chloride: a quaternary amine with unique pharmacologic properties.

Authors:  Raymond W Pak; Steven P Petrou; David R Staskin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

2.  Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence.

Authors:  R A Appell
Journal:  Rev Urol       Date:  2001

3.  Selecting a medical therapy for overactive bladder.

Authors:  H Henry Lai; Timothy B Boone; Rodney A Appell
Journal:  Rev Urol       Date:  2002

Review 4.  Clinical pharmacokinetics of trospium chloride.

Authors:  Oxana Doroshyenko; Alexander Jetter; Karl P Odenthal; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  [Drug therapy of female urinary incontinence].

Authors:  C Hampel; R Gillitzer; S Pahernik; S W Melchior; J W Thüroff
Journal:  Urologe A       Date:  2005-03       Impact factor: 0.639

Review 6.  Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Patrick D Meek; Samuel D Evang; Mina Tadrous; Dianne Roux-Lirange; Darren M Triller; Bora Gumustop
Journal:  Dig Dis Sci       Date:  2010-07-02       Impact factor: 3.199

Review 7.  Single compartment drug delivery.

Authors:  Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

8.  Increasing awareness and improving the care of urinary incontinence: highlights from the world health organization 2nd international consultation on incontinence july 1-4, 2001, paris, france.

Authors:  Christopher J Chermansky; Michael B Chancellor
Journal:  Rev Urol       Date:  2003

9.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.